Identifiable Intangible Assets and Goodwill (Tables)
|
12 Months Ended |
Dec. 31, 2018 |
|---|
| Goodwill and Intangible Assets Disclosure [Abstract] |
|
| Schedule of Finite-Lived Intangible Assets |
| | | | | | | | | | | | | | | | | | | | | | | | | | The following table provides the components of Identifiable intangible assets: | | | December 31, 2018 | | December 31, 2017 | (MILLIONS OF DOLLARS) | | Gross Carrying Amount |
| | Accumulated Amortization |
| | Identifiable Intangible Assets, less Accumulated Amortization |
| | Gross Carrying Amount |
| | Accumulated Amortization |
| | Identifiable Intangible Assets, less Accumulated Amortization |
| Finite-lived intangible assets | | | | | | | | | | | | | Developed technology rights(a) | | $ | 89,430 |
| | $ | (58,895 | ) | | $ | 30,535 |
| | $ | 89,550 |
| | $ | (54,785 | ) | | $ | 34,765 |
| Brands(a) | | 923 |
| | (708 | ) | | 215 |
| | 2,134 |
| | (1,152 | ) | | 982 |
| Licensing agreements and other | | 1,436 |
| | (1,140 | ) | | 296 |
| | 1,911 |
| | (1,096 | ) | | 815 |
| | | 91,788 |
| | (60,743 | ) | | 31,045 |
| | 93,595 |
| | (57,033 | ) | | 36,562 |
| Indefinite-lived intangible assets | | | | | | | | | | | | | Brands and other(a) | | 1,994 |
| |
|
| | 1,994 |
| | 6,929 |
| |
|
| | 6,929 |
| IPR&D(a) | | 2,171 |
| |
|
| | 2,171 |
| | 5,249 |
| |
|
| | 5,249 |
| | | 4,165 |
| |
|
| | 4,165 |
| | 12,179 |
| |
|
| | 12,179 |
| Identifiable intangible assets(b) | | $ | 95,954 |
| | $ | (60,743 | ) | | $ | 35,211 |
| | $ | 105,774 |
| | $ | (57,033 | ) | | $ | 48,741 |
|
| | (a) | The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held for sale during the fourth quarter of 2018 (see Note 2C), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A), (iii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E), as well as impairments of $2.9 billion of Developed technology rights (see Note 4). |
| | (b) | The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to the reclassification of $5.8 billion of intangible assets, net, ($6.3 billion total gross carrying amount) to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E). |
| | | | | | | | | | | Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: | | | December 31, 2018 | | | IH | | EH | | WRD | Developed technology rights | | 76 | % | | 24 | % | | — |
| Brands, finite-lived | | — |
| | 100 | % | | — |
| Brands, indefinite-lived | | — |
| | 100 | % | | — |
| IPR&D | | 65 | % | | 18 | % | | 17 | % |
|
| Schedule of Indefinite-Lived Intangible Assets |
| | | | | | | | | | | | | | | | | | | | | | | | | | The following table provides the components of Identifiable intangible assets: | | | December 31, 2018 | | December 31, 2017 | (MILLIONS OF DOLLARS) | | Gross Carrying Amount |
| | Accumulated Amortization |
| | Identifiable Intangible Assets, less Accumulated Amortization |
| | Gross Carrying Amount |
| | Accumulated Amortization |
| | Identifiable Intangible Assets, less Accumulated Amortization |
| Finite-lived intangible assets | | | | | | | | | | | | | Developed technology rights(a) | | $ | 89,430 |
| | $ | (58,895 | ) | | $ | 30,535 |
| | $ | 89,550 |
| | $ | (54,785 | ) | | $ | 34,765 |
| Brands(a) | | 923 |
| | (708 | ) | | 215 |
| | 2,134 |
| | (1,152 | ) | | 982 |
| Licensing agreements and other | | 1,436 |
| | (1,140 | ) | | 296 |
| | 1,911 |
| | (1,096 | ) | | 815 |
| | | 91,788 |
| | (60,743 | ) | | 31,045 |
| | 93,595 |
| | (57,033 | ) | | 36,562 |
| Indefinite-lived intangible assets | | | | | | | | | | | | | Brands and other(a) | | 1,994 |
| |
|
| | 1,994 |
| | 6,929 |
| |
|
| | 6,929 |
| IPR&D(a) | | 2,171 |
| |
|
| | 2,171 |
| | 5,249 |
| |
|
| | 5,249 |
| | | 4,165 |
| |
|
| | 4,165 |
| | 12,179 |
| |
|
| | 12,179 |
| Identifiable intangible assets(b) | | $ | 95,954 |
| | $ | (60,743 | ) | | $ | 35,211 |
| | $ | 105,774 |
| | $ | (57,033 | ) | | $ | 48,741 |
|
| | (a) | The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held for sale during the fourth quarter of 2018 (see Note 2C), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A), (iii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E), as well as impairments of $2.9 billion of Developed technology rights (see Note 4). |
| | (b) | The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to the reclassification of $5.8 billion of intangible assets, net, ($6.3 billion total gross carrying amount) to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E). |
| | | | | | | | | | | Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: | | | December 31, 2018 | | | IH | | EH | | WRD | Developed technology rights | | 76 | % | | 24 | % | | — |
| Brands, finite-lived | | — |
| | 100 | % | | — |
| Brands, indefinite-lived | | — |
| | 100 | % | | — |
| IPR&D | | 65 | % | | 18 | % | | 17 | % |
|
| Schedule of Expected Amortization Expense |
| | | | | | | | | | | | | | | | | | | | | | The following table provides the annual amortization expense expected for the years 2019 through 2023: | (MILLIONS OF DOLLARS) | | 2019 |
| | 2020 |
| | 2021 |
| | 2022 |
| | 2023 |
| Amortization expense | | $ | 4,581 |
| | $ | 3,552 |
| | $ | 3,467 |
| | $ | 3,217 |
| | $ | 2,920 |
|
|
| Schedule of Goodwill |
| | | | | | | | | | | | | | The following table provides the components of and changes in the carrying amount of Goodwill: | (MILLIONS OF DOLLARS) | | IH |
| | EH |
| | Total |
| Balance, January 1, 2017 | | $ | 30,134 |
| | $ | 24,315 |
| | $ | 54,449 |
| Additions(a) | | 572 |
| | 92 |
| | 664 |
| Other(b) | | 435 |
| | 404 |
| | 840 |
| Balance, December 31, 2017 | | 31,141 |
| | 24,811 |
| | 55,952 |
| Other(c) | | (2,264 | ) | | (277 | ) | | (2,541 | ) | Balance, December 31, 2018 | | $ | 28,877 |
| | $ | 24,534 |
| | $ | 53,411 |
|
| | (a) | IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A). |
| | (b) | Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold. |
| | (c) | Primarily reflects the impact of the reclassification of $2.0 billion to Assets held for sale during the fourth quarter of 2018 (see Note 2C), foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B). |
|